Physician profile
Devender N Akula
NPI 1285613133
$27,832.36
in general payments reported to CMS, 2019-2025
31 companies · $2,446 in 2025
The $2,446 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,508 · 2020: $8,183 · 2021: $1,262 · 2022: $1,570 · 2023: $4,009 · 2024: $2,853 · 2025: $2,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,315 · Food and Beverage: $3,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,315.16 |
| Food and Beverage | $3,993.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $8,385.26 | 2019-2025 | Carto 3, Nuvision Ice Catheter |
| Abbott Laboratories | $4,740.17 | 2019-2025 | Amplatzer Amulet, Aveir, Gallant |
| Pfizer INC. | $3,529.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,920.04 | 2019-2023 | |
| Medtronic, INC. | $2,285.65 | 2021-2025 | Micra, Sphere-9, Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $1,874.52 | 2019-2025 | Watchman Flx, Bodyguardian, Watchman Access System |
| Philips North America LLC | $1,223.92 | 2019-2025 | (Bs2) Lm Undivided, (5044) Mcot, (5050) Extended Holter |
| Impulse Dynamics (USA) INC. | $813.79 | 2022-2025 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $314.74 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $311.19 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $263.93 | 2019-2020 | |
| Atricure, INC. | $215.10 | 2019-2022 | |
| Cardiva Medical, INC. | $129.02 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Janssen Pharmaceuticals, INC | $122.14 | 2019-2024 | Xarelto |
| Irhythm Technologies, INC. | $115.71 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $82.83 | 2019-2021 | |
| Shockwave Medical, INC | $68.28 | 2022 | |
| Baxter Healthcare | $62.30 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Penumbra, INC. | $56.65 | 2025 | Indigo System |
| Preventice Services, LLC | $53.59 | 2019-2021 | |
| Daiichi Sankyo INC. | $43.62 | 2023-2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $34.45 | 2019 | |
| Altathera Pharmaceuticals LLC | $33.20 | 2022-2023 | Sotalol Hydrochloride |
| Amgen INC. | $30.21 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $25.84 | 2021-2022 | |
| Scpharmaceuticals INC. | $23.25 | 2025 | |
| W. L. Gore & Associates, INC. | $16.00 | 2023 | Gore Cardioform Septal Occluder |
| Cordis US Corp. | $15.49 | 2022 | |
| Mannkind Corporation | $15.17 | 2025 | |
| Cvrx, INC. | $13.28 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $13.05 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devender Akula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.